Unique Chinese Power
Location
Singular Medical ("Singular"), headquartered in Suzhou, China, has grown from scratch over the past years. The company, which started its business with two employees in an office of 5 sqm in 2017, now boasts 80 Chinese and around 20 American employees working for R&D, testing, and manufacturing centers in Suzhou, Beijing, and Irvine.
Team
Singular pools more than 100 talents in the areas of electronics, chip, software, structure, process, clinical medicine, and digital health from China and the United States, building a high-level team with rich expertise in product R&D, quality control, medical device registration and declaration, and business management. Current employees of Singular China, who worked for well-known enterprises like Medtronic, Abbott, Apple, Philips, and Siemens, have rich expertise in the medical field. More than half of the US employees have 15-30 years of pacemaker-related work experience. Some were BME fellows, ME fellows, or senior members of IEEE. Since its inception, Singular has cooperated with over 50 leading experts in the medical industry from China and the United States. Singular China has collaborated with several hospitals, such as Fuwai Hospital, as well as multiple universities, such as Fudan University. Singular America has maintained cooperation in the projects with prestigious institutions like the University of Michigan, the University of Notre Dame, and the University of Pittsburgh and has published several articles on public platforms.
Products
With a focus on screening, diagnosis, treatment, and monitoring of patients with arrhythmia and heart failure, Singular has developed and is developing a wide range of products, including cardiac disease screening devices, cardiac rhythm monitors, remote follow-up visiting system, Singular cloud platform, electrocardiographs, cardiac pacemakers, cardiac defibrillators, and other pacing/defibrillating leads. The product line covers various fields of implantable devices, digital health, and AI.
Intellectual Property Rights
Singular has applied for over 140 Chinese patents and multiple US patents and holds a number of FOS certificates on key technologies through cooperating with American professional law firms.
Markets
All Singular products will be supplied in the markets of China and other developing countries; and Singular innovative products (e.g., ICD) will be clinically tested, registered, and sold simultaneously in China and the US.
Leading Funds Investment
Singular has been favored by investors from the financing industry in recent two years and has obtained investment from leading funds at home and abroad, including Northern Light Venture Capital, SDIC Unity Capital, Qiming Venture Partners, Marathon Venture Partners, SND Financial Holdings, Lotus Lake Capital and Hwealth Capital. The company has been awarded multiple honorary titles, including the "2019 Future Healthcare VB100", "The Best New Enterprise Award in China's Healthcare Industry", "2021 Future Healthcare VB100", "2022 Medtech Outlook Best Medical Technology Company in China" and "2024 Potential Unicorn Company in Jiangsu Province".
Intellectual Property Rights
Singular has applied for over 140 Chinese patents and multiple US patents and holds a number of FOS certificates on key technologies through cooperating with American professional law firms.
Markets
All Singular products will be supplied in the markets of China and other developing countries; and Singular innovative products (e.g., ICD) will be clinically tested, registered, and sold simultaneously in China and the US.
Leading Funds Investment
Singular has been favored by investors from the financing industry in recent two years and has obtained investment from leading funds at home and abroad, including Northern Light Venture Capital, SDIC Unity Capital, Qiming Venture Partners, Marathon Venture Partners, SND Financial Holdings, Lotus Lake Capital and Hwealth Capital. The company has been awarded multiple honorary titles, including the "2019 Future Healthcare VB100", "The Best New Enterprise Award in China's Healthcare Industry", "2021 Future Healthcare VB100", "2022 Medtech Outlook Best Medical Technology Company in China" and "2024 Potential Unicorn Company in Jiangsu Province".
Offering safe and reliable solutions for patients with cardiac diseases with excellent technologies and innovative services.
Everlasting sound beating with every patient.
Singular aims to pursue perfect product quality with unparalleled responsibility and awe in mind.
Singular strives to make a long-term commitment to winning customers' trust with rigorous medical expertise and genuine innovation.
🔹▪️ Hard-working and enterprising
🔹▪️ Keeping scientific with rigorous attitudes
🔹▪️ Following respectful and inclusive ethics
Offering safe and reliable solutions for patients with cardiac diseases with excellent technologies and innovative services.
Everlasting sound beating with every patient.
Singular aims to pursue perfect product quality with unparalleled responsibility and awe in mind.
Singular strives to make a long-term commitment to winning customers' trust with rigorous medical expertise and genuine innovation.
🔹▪️ Hard-working and enterprising
🔹▪️ Keeping scientific with rigorous attitudes
🔹▪️ Following respectful and inclusive ethics
Singular Medical Listed in Official Release of 2024 Medical Device Industry Innovation Ecosystem Insight Evaluation
Singular Medical Listed in Grand Release of 2024 China Biopharma Leaders Top 100
Singular Medical Named 2024 Jiangsu Potential Unicorn Enterprise for Fourth Consecutive Year
Singular Medical Completes Enrollment in Multicenter Confirmatory Clinical Trial for Implantable Cardioverter Defibrillator (ICD)
Singular Medical Completes Enrollment in Multicenter Confirmatory Clinical Trial for Implantable Cardiac Monitor (ICM)
Singular Medical has developed the first domestically produced ICD (Implantable Cardioverter-Defibrillator)
Singular Medical's Implantable Cardiac Monitor (ICM) has obtained approval as an innovative medical device
Singular Medical's Anbo® ICD Included in the 2024 China Medical Device Star Innovation List
Winning Again! Singular Medical Wins the VBEF2024 Annual Innovative Product Award in the Healthcare Industry
Singular Medical's Anbo® ICD Successfully Achieves First Painless Treatment in Real-World Setting
Singular Medical's Anbo ICD Achieves First Real-World SVT Discrimination in a Dextrocardia Patient: A Case Report
Singular Medical Selected as a 2023 Suzhou 'Unicorn' Cultivation Enterprise
Setting Sail on a New Journey - Singular Medical's Implantable Cardiac Defibrillator (ICD) Successfully Enrolls First Participant in Registration Clinical Trial
Singular Medical's Implantable Cardiac Monitor (ICM) Successfully Enrolls First Participant in Registration Clinical Trial
Singular Medical Selected as a Potential Unicorn Company in Jiangsu for Two Consecutive Years
Singular Medical's Implantable Cardiac Defibrillator (ICD) Approved as Innovative Medical Device
Singular Medical Selected for "Forbes Asia's Top 100 to Watch" list.
In May 2023, Singular successfully completed the first domestic ICD human clinical trial and obtained the report.
• Singular closed its B+ round of financing of hundred million RMB.
• Singular became the first enterprise to join the newly established Domestic ICD Clinical Expert Working Group.
Singular Medical Listed in Official Release of 2024 Medical Device Industry Innovation Ecosystem Insight Evaluation

Singular Medical Listed in Grand Release of 2024 China Biopharma Leaders Top 100

Singular Medical Named 2024 Jiangsu Potential Unicorn Enterprise for Fourth Consecutive Year

Singular Medical Completes Enrollment in Multicenter Confirmatory Clinical Trial for Implantable Cardioverter Defibrillator (ICD)

Singular Medical Completes Enrollment in Multicenter Confirmatory Clinical Trial for Implantable Cardiac Monitor (ICM)

Singular Medical has developed the first domestically produced ICD (Implantable Cardioverter-Defibrillator)

Singular Medical's Implantable Cardiac Monitor (ICM) has obtained approval as an innovative medical device

Singular Medical's Anbo® ICD Included in the 2024 China Medical Device Star Innovation List

Winning Again! Singular Medical Wins the VBEF2024 Annual Innovative Product Award in the Healthcare Industry

Singular Medical's Anbo® ICD Successfully Achieves First Painless Treatment in Real-World Setting

Singular Medical's Anbo ICD Achieves First Real-World SVT Discrimination in a Dextrocardia Patient: A Case Report

Singular Medical Selected as a 2023 Suzhou 'Unicorn' Cultivation Enterprise

Setting Sail on a New Journey - Singular Medical's Implantable Cardiac Defibrillator (ICD) Successfully Enrolls First Participant in Registration Clinical Trial

Singular Medical's Implantable Cardiac Monitor (ICM) Successfully Enrolls First Participant in Registration Clinical Trial

Singular Medical Selected as a Potential Unicorn Company in Jiangsu for Two Consecutive Years

Singular Medical's Implantable Cardiac Defibrillator (ICD) Approved as Innovative Medical Device

Singular Medical Selected for "Forbes Asia's Top 100 to Watch" list.

In May 2023, Singular successfully completed the first domestic ICD human clinical trial and obtained the report.

• Singular closed its B+ round of financing of hundred million RMB.

• Singular became the first enterprise to join the newly established Domestic ICD Clinical Expert Working Group.

• Singular was rated as one of the "2022 Top MedTech Companies in China" by Medtech Outlook Magazine.

• Singular was included in the 2021 Suzhou "Unicorn" incubating enterprises list.

• Singular was nominated as a potential unicorn enterprise in Jiangsu Province.

• Singular obtained its B round of financing at several hundred million yuan.

• Singular was ranked as one of the top 100 innovative medical device companies.

Copyright© 2020-2023 Suzhou Singular Medical Co., Ltd. 苏ICP备19036489号-1
Copyright© 2020-2023 Suzhou Singular Medical Co., Ltd. 苏ICP备19036489号-1